A current
trend in drug development involves the use of high molecular
weight, branched, and functionalized polymers for protein conjugation
and drug delivery. Accurately characterizing these polymers is critical
to control the product quality, to monitor the stability, and ultimately
to ensure the drug efficacy and patient safety. However, due to the
heterogeneity in size, the multiplicity of functional groups, and
the highly convoluted charge-distribution profile in mass spectra,
the characterization of these polymers is highly challenging from
both chromatography and mass spectrometry perspectives. To overcome
these challenges, we developed a strategy utilizing charge-reduction
mass spectrometry (CRMS) coupled with two-dimensional HPLC (2D-LC).
We then applied the workflow to characterize a 40 kDa 8-arm polyethylene
glycol (PEG) functionalized with a maleimide terminal group for protein
conjugation. The development was carried out in stages, where first
we focused on the development of a CRMS method to simplify the charge
profile of the polymers and then coupled it to HPLC to obtain discernible
mass spectra of key impurities and degradants. Second, the CRMS method
was applied to an investigation of the size-variant impurity resolved
by reversed-phase size-exclusion 2D-LC. Finally, a separate size-exclusion
reversed-phase 2D-LC-CRMS method was developed to capture a wider
range of process-related impurities and reaction intermediates from
the PEG–maleimide polymers throughout the conjugation process.
The combination of these experiments using the 2D-LC-CRMS strategy
enables the sensitive characterization of the entire impurity profile
of the high molecular weight multifunctionalized PEG–maleimide
conjugation intermediate.